IL6 and COVID-19: Because HM and recent chemotherapy have been associated with poor outcomes among patients with cancer and COVID-19, the anti-inflammatory effects of nirmatrelvir-ritonavir and azvudine were determined via the expression levels of IL-6, PCT, CRP, and various serological laboratory indicators.